Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events.

@article{Sozio2014ActivatedRF,
  title={Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events.},
  author={Margaret S. Sozio and Naga Chalasani},
  journal={Hepatology},
  year={2014},
  volume={60 5},
  pages={1786-8}
}
Background & Aims: Two randomized controlled studies have evaluated the effect of recombinant Factor VIIa (rFVIIa) on variceal bleeding in cirrhosis without showing significant benefit. The aim of the present study was to perform a metaanalysis of the two trials on individual patient data with special focus on high risk patients. Methods: The primary… CONTINUE READING